QQ客服 官方微博 反馈留言

	The role of concurrent chemotherapy for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A systematic review and meta-analysis
	Fang Liu; Tao Jin; Lei Liu; Zhongzheng Xiang; Ruonan Yan; Hui Yang
刊名	PLoS One
	2018
卷号	Vol.13 No.3页码:e0194733
ISSN号	1932-6203
URL标识	查看原文
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/1823278
专题	四川大学
作者单位	1.Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China 2.The Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China 3.Department of Otolaryngology-Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China George Washington University Milken Institute of Public Health, UNITED STATES
推荐引用方式 GB/T 7714	Fang Liu,Tao Jin,Lei Liu,et al. The role of concurrent chemotherapy for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A systematic review and meta-analysis[J]. PLoS One,2018,Vol.13 No.3:e0194733.
APA	Fang Liu,Tao Jin,Lei Liu,Zhongzheng Xiang,Ruonan Yan,&Hui Yang.(2018).The role of concurrent chemotherapy for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A systematic review and meta-analysis.PLoS One,Vol.13 No.3,e0194733.
MLA	Fang Liu,et al."The role of concurrent chemotherapy for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A systematic review and meta-analysis".PLoS One Vol.13 No.3(2018):e0194733.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。